Docking and quantitative structure–activity relationship of bi-cyclic heteroaromatic pyridazinone and pyrazolone derivatives as phosphodiesterase 3A (PDE3A) inhibitors
Fig 4
Template-based alignments of PDE3A inhibitors.
(a) Sets 2–4, (b) sets 1 and 5 in alignment PPA, and (c) sets 1 and 5 in PA. Pyrazolopyridine and pyridazinone/pyrazolone moieties are highlighted in orange and magenta, respectively.